BioMed Research International / 2021 / Article / Tab 1 / Research Article
Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer Table 1 The clinical characteristics of advanced NSCLC in training and validation cohort (
(%)).
Characteristics Training set Validation set TCGA ( ) GSE41271 ( ) GSE81089 ( ) Age (year) <65 82 (42.71) 33 (36.26) 13 (36.11) ≥65 110 (57.29) 58 (63.74) 23 (63.89) Gender Male 117 (60.94) 54 (59.34) 14 (38.89) Female 75 (39.06) 37 (40.66) 22 (61.11) Histological type LUAD 104 (54.17) 55 (60.44) 27 (75) LUSC 88 (45.83) 36 (39.56) 9 (25) Metastasis (M_stage) M0 160 (83.33) 85 (93.41) 33 (91.67) M1 32 (16.67) 6 (6.59) 3 (8.33) Lymph node (N_stage) N0 30 (15.63) — — N1 47 (24.48) — — N2 106 (55.21) — — N3 9 (4.69) — — Tumor invasion (T_stage) T1 21 (10.94) — — T2 85 (44.27) — — T3 45 (23.44) — — T4 41 (21.35) — — Tumor stage III 160 (83.33) 85 (93.41) 33 (91.67) IV 32 (16.67) 6 (6.59) 3 (8.33) Smoking Yes 166 (86.46) 80 (87.91) — No 26 (13.54) 11 (12.09) —
Abbreviations: LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma.